NI
PCRX icon

Numeric Investors’s Pacira BioSciences PCRX Stock Holding History

Numeric Investors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,400
Closed -$239K – 1124
2016
Q4 		$239K Sell
7,400
-3,300
-31% -$110K ﹤0.01% 968
2016
Q3 		$366K Buy
+10,700
New +$419K ﹤0.01% 886

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Numeric Investors's PCRX Position: Q1 2017 in Review

Numeric Investors sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 7,400 shares — an estimated $239K sold.

Numeric Investors first reported a position in PCRX in Q3 2016 and held it in 2 quarters. The position peaked at $366K in Q3 2016. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

  • Numeric Investors reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
  • Numeric Investors sold 7,400 Pacira BioSciences shares in Q1 2017, an estimated $239K.
  • Numeric Investors first reported a position in Pacira BioSciences in Q3 2016 and held it in 2 quarters.
  • Numeric Investors's Pacira BioSciences position peaked at $366K in Q3 2016.
  • 192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Numeric Investors's 13F filing for Q1 2017, filed 15 May 2017.